Ticker Hub
PTGX — AI Analysis & Sentiment
5 recent AI-generated analyses for PTGX. Sentiment and confidence insights updated continuously.
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Protagonist Therapeutics reported a significant turnaround to net income in Q1 2026, fueled by a $250 million cash infusion from recent regulatory ...
May 5, 2026Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Protagonist Therapeutics' opt-out decision for rusfertide significantly enhances its financial position with immediate payment eligibility and subs...
Apr 29, 2026Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Protagonist announced robust one-year Phase 3 data for its approved drug ICOTYDE, reinforcing its commercial viability and potential for future roy...
Mar 28, 2026Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
The FDA approval of ICOTYDE is a game-changer for Protagonist Therapeutics, validating its pipeline and providing a clear path to substantial futur...
Mar 18, 2026Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Protagonist's NDA submission for rusfertide and anticipated regulatory decisions for two drugs this year mark crucial steps towards commercializati...
Feb 25, 2026